StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

537 Study Matches

The Experiences of Asexual Individuals in Health and Sexual Education Classes: Influences on Identity, Body Image, Personal Health, and Patient-Provider Relationships

This project explores the experiences of asexual individuals in health and sexual education classes. Specifically, we are interested in the structure of the courses and the extent to which LGBTQIA+ identities were included in the curriculum. Additionally, we are interested in ways health and sexual education classes have since influenced how asexual individuals view and feel about their bodies, as well as how they approach their personal health. Individuals currently identifying as asexual will be surveyed about their experiences and will have the change to provide recorded interviews if desired.

Participants will be asked to complete an online survey that is expected to take 30-40 minutes. Participants also have the opportunity to elaborate on their survey responses during a recorded Zoom interview.

Participants may enter a raffle to win one of 10 Amazon.com giftcards

No
 

Gail Boldt
Brandon D'Souza - at bdsouza@pennstatehealth.psu.edu or 614-827-5660
Curriculum and Instruction (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00025052
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
English speaking
Over the age of 18
Took a health/sexual education class in the U.S since the year 2000
Currently identifies as asexual (or an asexual sub-identity)

Exclusion Criteria:
Non-English speaking
Under the age of 18
Did not take a health/sexual education class in the U.S since the year 2000
Does not currently identify as asexual (or an asexual sub-identity)
Education, Mental & Behavioral Health
Survey(s)
I'm interested
Share via email

A Phase Ib/11 Study of Propranolol with fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma

This research is being done to find out the safety of propranolol and, identify the maximum tolerated dose of propranolol that can be administered in combination with pembrolizumab in patients with unresectable stage III and stage IV melanoma. This study will evaluate this novel combination of pembrolizumab and propranolol to see what effect it may have on how your cancer responds to the treatment combination.

Phase II *propranolol twice a day. *pembrolizumab by an infusion every 3 weeks. *May receive treatment with pembrolizumab and propranolol for up to 24 months from the time they began treatment with the combination. Procedures to be done:.  A medical history  A physical exam  ECOG Performance Status  Perceived Stress Scale questionnaire  An assessment of tumor by scan. Scans may include: o Computed tomography (CT), with or without contrast. o Magnetic resonance imaging (MRI) or head CT with IV contrast  Blood tests: o Approximately 2 tablespoons for routine testing, such as a complete blood count and a comprehensive metabolic panel  Pregnancy test  Urinalysis  Electrocardiogram  A sample of tumor from a previous biopsy or sample taken Phase 1 portion of the study, these evaluations/tests will also occur on Day 8 of Cycle 1  Review concomitant medications.  Physical Exams  ECOG Performance Status  Perceived Stress Scale questionnaire  Blood tests: o Every 3 weeks o At 3 weeks and 6 months or discontinuation of treatment (whichever comes sooner) and at disease progression o Every 3 weeks: Approximately 1 tablespoon for tests that monitor your blood sugar levels and thyroid function o Every week for the first 6 weeks then every cycle for another 6 weeks  Assessment of cancer by CT or MRI. These assessments will be performed every 12 weeks(± 14 days). The first assessment will be after completing Cycle 4. If their cancer is found to be improving, repeat the CT and MRI scans in about 12 weeks.  EKG: Once treatment begins, this will be done every cycle prior to receiving pembrolizumab for the first 5 cycles.  Adverse events  Tumor Biopsy: A tumor biopsy (only in phase II) will be obtained at the 12 weeks after initiation of treatment.Tumor biopsy will be optional for phase II patients.. Safety Follow-Up: After all study treatment has stopped, end of treatment visit, which will be approximately 30 days after their last dose of study drug or before starting a new treatment  Medical History:  Concomitant medications  complete physical examination  ECOG Performance Status  Perceived Stress Scale assessment  Adverse events  Survival status  Blood tests: o Follow- Up Phase 3 Month and 6 Month Follow- up After Treatment blood collected. The following assessments will be performed at 3 months and 6 months after the safety follow-up visit. Review concomitant medications  Physical examination  ECOG Performance Status  Adverse events  Survival Status  Blood tests:  CT of chest, abdomen and pelvis, or other areas as needed Long Term Survival Follow- Up: After your 3 month and 6 month follow up visits or if they progress, will be contacted every 6 months (±30 days)

Yes
 

Joseph Drabick
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03384836
STUDY00010009
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age >=18 years.
Participants must be newly diagnosed, treatment-naive with histologically confirmed stage IIIC unresectable melanoma or stage IV melanoma.
Have measurable disease per RECIST v1.1
Have an ECOG performance status 0-1

Exclusion Criteria:
Participants who have received previous immunotherapy for any cancer (excluding melanoma) including PD-1/PD-L1 inhibitors but not interferons and CTLA-4 inhibitors.
Participants with chronic autoimmune diseases
Other invasive cancers diagnosed < 3 years back that required systemic treatment. If diagnosed with other invasive cancer ≥ 3 years, should have complete recovery from all systemic toxicity except neuropathy and alopecia
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Advancing the use of immersive virtual environments to study the effects of racism on eating behavior in an Asian American population

During the COVID-19 pandemic, Asian Americans have faced a rise in overt racism, with thousands of hate incidents reported. This has had a bigger impact on young Asian American adults, leading to emotional distress and health problems. A theory by Harrell suggests that experiencing racial discrimination can harm mental and physical well-being due to stress. Past studies have shown a connection between racial discrimination stress and health issues like obesity and mental disorders. However, there's a need to understand the cultural and emotional factors involved. This research aims to explore how racial discrimination affects Asian Americans' food choices by looking at stress responses and cultural influences. Using surveys, experiments, psychophysiology, and virtual reality, the study will investigate how cultural identity affects stress reactions and subsequent food decisions after racial discrimination experiences.

Hello, We are recruiting Asian Americans with Japanese, Chinese, or Korean heritage for a paid research study. We want to understand how racism affects food choice in a virtual reality (VR) environment. To participate in this study, you will need to complete an informed consent form, and answer questions prior to your arrival at the lab. You will have to come to the lab to watch a video of anti-Asian racism incidents that happened during the COVID-19 pandemic, and answer questions before and after the video. Last, you will make food choices in the VR environment. Participation will require three hours or more of fasting before arrival at the lab. You will be paid $25 in a gift card for your participation. If you come to the lab but do not complete the study, you will still be paid. Please continue to the next page to read the informed consent if you are interested in participating. If you are not, please exit this page. https://redcap.link/lp1wq7uu

$25 Amazon gift card

Yes
 

Travis Masterson
Christina Blackmon - at cmb8633@psu.edu
Nutritional Sciences (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT00000000
STUDY00023365
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Self-identified as Asian American of Japanese, Chinese or Korean heritage
Aged between 18 and 21 at the start of the study
Born in the US or lived in the U.S. since your 10th birthday or earlier
Self-reported having fasted for at least 3 hours prior to the start of the study

Exclusion Criteria:
Not self-identified as Asian-American of Japan, China or Korea heritage
Not aged between 18 and 21 at the start of the study
Not born in the US or not having lived in the U.S. since your 10th birthday or earlier
Self-reported having fasted for less than 3 hours prior to the start of the study
Has epilepsy or a cognitive disability
Food & Nutrition, Mental & Behavioral Health
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Understanding the Media Literacy Competencies of Today’s College Students

This study will involve surveying college students regarding their media literacy competencies and experiences with media literacy education.

No
 

Hans Schmidt
Hans Schmidt - at hcs10@psu.edu or 610-892-1251
Academic Affairs (BRANDYWINE)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00013446
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
College student
18 years of age or older

Exclusion Criteria:
Not 18 years of age or older
Education
I'm interested
Share via email

Concussion-Prognosis

Using micro-RNA in saliva coupled with survey data as a prognostic tool with the ability to guide clinical management of concussions

During their baseline visit participants will complete a saliva swab, surveys, balance test and brief neurocognitive test. Day 7, participants will complete a saliva swab and 2 surveys. Day 30, participants will complete a saliva swab and 4 surveys. The baseline visit is the only in-person visit, day 7 and day 30 are done remotely. All surveys are completed online and day 7 and day 30 saliva swabs are sent home with the participants and sent back in a prepaid mailer on day 30.

$40

Yes
 

Jayson Loeffert
Brennen Harding - at bharding@pennstatehealth.psu.edu or 717-531-5656
Family and Community Medicine (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT04582682
SITE00000820
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
13-18 years old
Diagnosis of concussion

Exclusion Criteria:
more than 48 hours after injury
Neurology, Sports Medicine
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Prospective Cohort Assessing Novel Biomarkers of Early Pregnancy

The purpose of this research is to take and store blood, urine samples from pregnant women diagnosed by a positive pregnancy test or by ultrasound imaging. The purpose of this study is to determine a better way to diagnose the location and/or viability (chance of survival) of a pregnancy, as compared to current clinical care. Many women are found to be pregnant by a hCG (human chorionic gonadotropin) test which detects a hormone that is indicative of pregnancy. However, in early pregnancy, it is often difficult to see the pregnancy by ultrasound, which is called a pregnancy of unknown location (PUL). In early pregnancy, doctors do many tests (including blood tests and ultrasounds) to try to determine how far along the pregnancy is, whether it is healthy, and most importantly whether the pregnancy is growing in the right place. The doctors running this research project are trying to see if there are substances (biomarkers) in the blood or urine of a pregnant woman that can tell whether the pregnancy is a normal, healthy pregnancy, an ectopic pregnancy, or if pregnancy is not viable (miscarriage). To do this, blood and/or urine samples are being collected from women who have a pregnancy of unknown location, an ectopic pregnancy, women who are having a miscarriage, and women with a healthy growing pregnancy. The study will then look at a pre- determined panel of biomarkers that have been shown to be elevated (higher) or decreased (lower) in different types of pregnancy to determine the effectiveness and accuracy of this test in earlier diagnosing the viability and location of early pregnancy.

There will be one visit at the visit participants will be consented and following consenting blood and urine will be collected.

$25.00

Yes
 

Sarah Horvath
OBGYN Research at OBGYNResearch@pennstatehealth.psu.edu or 717-531-0003, ext=320358
Obstetrics and Gynecology (HERSHEY)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00018551
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pregnancy diagnosed by a positive serum human chorionic gonadotropin (hCG) test
Live intrauterine pregnancy through 14 weeks, diagnosed by ultrasound demonstrating fetal heart motion
Diagnosed ectopic pregnancy
Pain or bleeding or at risk for ectopic pregnancy
Women seeking confimation of a pregnancy with a urine or serum pregnancy test (less than 14 weeks)

Exclusion Criteria:
Not a Penn State Health Patient
Pregnancy & Infertility, Women's Health
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

POSTA: Protocol for Oral Somatosensation and Texture Appreciation

The purpose of this study is to collect normative data related to orofacial (lip/tongue) somatosensation (touch sensation) in healthy adults across the adult lifespan. This data will be compared to a select clinical population, those with Parkinson's disease.

There will be one data collection session lasting approximately 90 minutes. Participants may be invited back for a second session approximately 4 weeks later to repeat the testing session During the sessions, participants will answer a series of questions about their eating and drinking preferences, they will be asked to provide a speech sample by repeating a series of syllables, words, and sentences, as well as providing a spontaneous speech sample. All participants will be asked to complete a series of sensory tests where small plastic objects are placed on their lip, tongue, and finger tip. Participants will be asked when they feel the pressure/texture and when they do not.

Yes
 

Nicole Etter
Nicole Etter - at oppal@psu.edu or 814-863-2021
Communication Sciences and Disorders (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00024173
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
English-speaking
Hearing and cognition within functional limits to complete speaking tasks
Clinical Group: Diagnosed with Parkinson's disease (PD)

Exclusion Criteria:
Have an injury to the lower face
have an active lesion to the lower face (ie cold sore, fever blister, etc)
have had a dental visit in the last month that involved general or local anesthesia to the oral region
exhibit symptoms of Tardive Dyskinesia secondary to anti-psychotic drug use
report current or recovering from a viral illness like Bell’s Palsy or Shingles
Food & Nutrition, Neurology
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Linking olfactory deficits to memory impairment and AD neurodegeneration

The purpose of this voluntary research study is to find out more about changes in the brain as we age. This study is trying to determine if magnetic resonance imaging (MRI), genetic variations, amyloid positron emissions tomography (PET), neuropsychological testing, and smell tests can be used to evaluate memory loss and cognitive impairment.

You will be asked to come to the research site once a year for 5 years. Annual (and semi-annual) procedures include completing smell tests, neuropsychological tests, magnetic resonance imaging (MRI), interview. One-time procedures include provide blood sample, amyloid PET scan (if indicated), and optional lumbar puncture.

Up to $300 a year

Yes
 

Prasanna Karunanayaka
Katie Geesey - at kgeesey@pennstatehealth.psu.edu or 717-531-0003, ext=321589
Radiology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00018557
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Individuals between ages 55-85

Exclusion Criteria:
Non-English speaking
Smell impairment
Women who are pregnant or breastfeeding
Currently smoke
Have claustrophobia
Neurology
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

The Association Between Head Cooling and Cognition, EEG Patterns, Neuroinflammatory Cytokines, and Mental Health

This research is being done to find out the effects of head cooling on cognition, brain activity as seen in EEG scans, inflammation of the brain, and mood in healthy subjects. What is specifically meant by healthy subjects in the context of this study is subjects who are not currently recovering from a traumatic brain injury.

This study includes an 8-day regimen of head cooling or rest at an average of 30 minutes per day, non-invasive cheek swabs used to collect saliva samples, and non-invasive brain activity testing and questionnaires.

$40

Yes
 

Semyon Slobounov
Laura Cooney - at lmc6418@psu.edu or 267-421-2419
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT06542419
STUDY00025196
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18-24 years
Currently NOT recovering from a brain injury

Exclusion Criteria:
Under 18 years
Currently recovering from a brain injury
Mental & Behavioral Health
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Accessibly of Conversational Agents with Deaf or Blind Users

Using small focus groups, this work aims to understand the experiences, challenges, perceptions, and opportunities for the use of conversational agents (e.g Amazon Alexa and Siri) for users with visual or hearing impairments, with the goal of developing more accessible and inclusive systems.

Yes
 

Johnna Blair
Johnna Blair - at jlb883@ist.psu.edu or 814-706-8412
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00010384
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Either, blind or visually impaired,
Or, hard of hearing or deaf using cochlear implant or other aided hearing device
Currently 18 years of age or older
English language speakers

Exclusion Criteria:
Minors, under the age of 18
Non-English language speakers
Language & Linguistics, Vision & Eyes
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Exploring the Immediate Psychosocial and Self-Management Support Needs of Individuals Newly Diagnosed with Type 2 Diabetes (T2D)

To find out the kind of support someone newly diagnosed with type 2 diabetes will need following diagnosis.

No
 

Michelle Boakye
Michelle Boakye - at mdb521@psu.edu or 814-699-1783
NON-PSU SITE
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00017593
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
newly diagnosed with type 2 diabetes(past 12 months)
Age 20 years or older
agree to participate in online focus group

Exclusion Criteria:
old cases of type 2 diabetes
individuals below 20 years
diagnosed with other types of diabetes
Diabetes & Hormones
I'm interested
Share via email

Pennsylvania Adoptees Longitudinal Study (PALS)

This study will examine various factors within the home of children adopted from the child welfare system between the ages of 4 and 10 that may impact their development. The first visit will occur remotely via Penn State Health Microsoft Teams; the second visit is optional and will occur within 4 weeks of the first visit at the Transforming Lives of Children Center in Harrisburg, PA; and the third visit will occur one year after the first visit, when research staff will travel to participants' homes. This research will help understand the factors that impact the development of children adopted from the child welfare system and how we may better serve these children and their families.

The child and parent will be asked to complete interviews, questionnaires and various tasks. Parents may also be asked to complete questionnaires online. Participation will last for one year and include the following: -One visit occurring remotely via PSH Microsoft Teams -One visit at the Transforming the Lives of Children Center in Harrisburg, PA, four weeks after Zoom visit (optional) -Final visit at home will occur one year after the first Zoom visit

$225

Yes
 

Brian Allen
pals@pennstatehealth.psu.edu 717-531-0003, ext=321713
Pediatrics: Child Abuse (HERSHEY)
 

All
All
This study is also accepting healthy volunteers
STUDY00013344
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Child age between 4 and 10
Child legally adopted by the caregiver
The same caregiver will participate in each of the visits

Exclusion Criteria:
Child diagnosed with intellectual disability
A biological parent resides in the same home as the child
Children's Health, Mental & Behavioral Health
I'm interested
Share via email
Show 17 locations

Study Locations

Hide all locations
Location Contacts
Altoona, PA ,
Carlisle, PA ,
DuBois, PA ,
Erie, PA ,
Greater Philadelphia Area, PA ,
Greater Pittsburgh Area, PA ,
Harrisburg, PA ,
Hazleton, PA ,
Hershey, PA ,
Mont Alto, PA ,
Reading, PA ,
Schuylkill Haven, PA ,
Sharon, PA ,
State College, PA ,
Wilkes-Barre/Scranton Area, PA ,
Williamsport, PA ,
York, PA ,

Graduate Students’ Experience with Online Professional Profiles and Social Media

With the development of information and communication technologies, Social Network Sites and other online platforms can be great resources for career-related information and social networking. Despite the evidence of possible professional benefits, it remains unclear whether graduate students’ experiences with building online career profiles and social networking are positive. Therefore, this study aims to understand graduate students’ experience with professional practices on the Internet concerning their motivations, benefits, and risks.

No
 

Chuhao Wu
Chuhao Wu - at cjw6297@psu.edu
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00019028
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
An active graduate student at University Park campus

Exclusion Criteria:
NA
Education
I'm interested
Share via email

AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

This is a multicenter evaluation of seladelpar, administered as a once-daily oral capsule, in a placebo-controlled study in subjects with Primary Biliary Cholangitis (PBC). This study (156 weeks) will enroll approximately 192 subjects. The population to be studied is patients with PBC and compensated cirrhosis restricted to Child-Pugh (CP)-A or CP-B. Primary Objectives Efficacy: To evaluate the effect of seladelpar compared to placebo. Safety: To evaluate the safety of seladelpar over 156 weeks of treatment compared to placebo. Study visits: up to 18 in person visits. Blood samples will be collected at each visit for safety measures as well and questions about your health and medicines you might be taking.

There will be 18 in person visits. safety assessments will be conducted at each visit. Participants will be required to take study drug as directed.

$1350

Yes
 

Karen Krok
Laurie Peiffer - at lpeiffer@pennstatehealth.psu.edu or 717-531-5226
Medicine: Gastroenterology and Hepatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06051617
STUDY00022898
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
diagnosis of PBC
Elevated Alkaline Phosphatase (ALP)
documented cirrhosis

Exclusion Criteria:
history of liver transplant
decompensated cirrhosis
portal vein thrombosis
hospitalization for liver complication within 12 weeks
HIV
Digestive Systems & Liver Disease
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Campus Environments and Student Health

The purpose of this study is to learn about the relationship between the campus environment and students’ health. It involves a survey consisting questions about campus-related activities, COVID-19, physical activity and health, environmental perceptions, and demographic information.

There will be an online survey that will take about 20-30 minutes. No need to meet in-person.

No
 

Amaryllis Park
Amaryllis Park - at ahp5234@psu.edu or 281-628-6496
Landscape Architecture (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00022472
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Currently enrolled as a student (part-time or full-time)
At least 18 years old or older

Exclusion Criteria:
Younger than 18 years old
Mental & Behavioral Health
I'm interested
Share via email

Dysgeusia and Anosmia in Head and Neck Cancer Patients: Long Term Outcomes

The primary aim of this study is to understand taste changes after head and neck cancer treatment, especially long term taste disturbance, using various methods including online surveys, Teams interviews, at home taste and smell tests, and MRIs.

The purpose of this voluntary research study is to identify taste changes in patients treated for head and neck cancer. We are recruiting healthy participants over the age of 40 as well as head and neck cancer survivors who were treated 3 or more years ago. The overall study consists of multiple parts, which are explained along the way. You can choose to participate in this portion, which is an online survey, and nothing else, or all of the invited components. • The survey will take approximately 10 minutes of your time. • Completion of this survey is voluntary and you are not required to complete it if you do not wish to do so. • At the end of the survey you will be asked about your willingness to participate in other portions of this study. These include at-home taste and smell tests over Teams and a Teams interview about your taste and smell function. Participating in these tasks is optional and not required. If you complete the smell and taste tests at home you may be invited to have an MRI scan.

Max of $75: No compensation for the survey, $15 giftcard for 1-hour interview (optional), $15 giftcard for at-home taste/smell tests (optional), $50 giftcard for MRI at Hershey Med Center (optional).

No
 

Neerav Goyal
Hanel Eberly - at HNCtaste@pennstatehealth.psu.edu
Otolaryngology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00019457
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Able to give consent
Over the age of 40
English Speaking

Exclusion Criteria:
Under 40 years of age
have undergone a total glossectomy
currently have an upper respiratory infection, sinus infection, or ear infection
Cancer
I'm interested
Share via email

Comparing Mechanisms of Pattern Learning

The purpose of the proposed plan of research is to investigate the types of patterns that human adults with or without a history of language/ learning difficulties tap into as they learn.

Our study involves an initial testing session lasting between 1-2 hours, followed by up to two additional sessions for eligible participants. As part of our study, you will take part in some speaking, listening, learning, and visual processing tasks.

up to $75

No
 

Roger Beaty
jzp6211@psu.edu
Psychology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00017229
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-28
Only speaks English fluently
Normal or corrected-to-normal vision/ hearing
Minimum of high school education
May have a history of language/ learning difficulties

Exclusion Criteria:
History of neurological injury or disease
Speaks more than one language
Under age 18
Over age 28
Does not have minimum of high school education
Language & Linguistics
Not applicable
I'm interested
Share via email

Emotion Regulation and Mother-Infant Synchrony

The aim of this study is to better understand emotion regulation in infants by measuring brain, behavior, and mother-infant relational mechanisms. We plan to collect simultaneous brain activation in mothers and infants while they engage in a face-to-face interaction. We will then test associations between individual brain activation, mother-infant brain synchrony, and infant emotion regulation behaviors.

Participants complete questionnaires online, then come in for 1 in-person visit. Mother and baby complete a play and a neutral task while fNIRS is collected from them simultaneously.

40

Yes
 

Berenice Anaya
Berenice Anaya - at bua25@psu.edu
Psychology (UNIVERSITY PARK)
 

All
All
This study is also accepting healthy volunteers
STUDY00018109
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Infants who are 4 months and their mother.
Infants born 3 weeks within their due date.
Infants of a birth weight > 2500 g.
Infants with NO serious medical complications.
English-speaking families.

Exclusion Criteria:
Infants who were < 2500 g at birth.
Infants who experienced any serious medical complications.
Infants who were born > 3 weeks before the indicated gestational period.
Families who do not understand and do not speak English
Children's Health, Neurology
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Olfactory tools for COVID-19 screening and surveillance

This a collaborative multisite NIH funded project to develop smell tests as a rapid low cost way to screen for Covid19 infections. The lead institution is the University of Florida, and this project is being entered into CATS to create a Reliance Agreement under the NIH single IRB rules (sIRB).

No
 

John Hayes
Elisabeth Weir - at efw5195@psu.edu
Food Science (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
SITE00000951
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Aged 18 to 99
COVID19 negative
COVID19 positive
Able to Consent in English

Exclusion Criteria:
Inability to provide consent
History of known pre-existing olfactory or taste disorder
History of head trauma with loss of consciousness
History of neurodegenerative disease
COVID-19
I'm interested
Share via email

Predicting Concussion Outcomes with Salivary miRNA

The purpose of this study is to identify changes in salivary micro ribosomal nucleic acid (miRNA) expression that are predictive of symptom duration and severity following mild traumatic brain injury (mTBI) in children. The primary endpoints of this study are as follows: 1) Characterization of brain-related miRNA in the saliva of 250 children with mTBI and 200 age- and gender-matched controls between the ages of five and twenty-three years. 2) Identification of a set of salivary miRNAs that is predictive of duration and severity of mTBI symptoms.

Saliva collection and surveys at baseline, 7 days, and 30 Days

$20

Yes
 

Jayson Loeffert
Brennen Harding - at bharding@pennstatehealth.psu.edu or 717-531-5656
Family and Community Medicine (HERSHEY)
 

All
All
This study is also accepting healthy volunteers
NCT02901821
STUDY00003729
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
5 to 23 years of age
Seen in the Penn State Pediatric Concussion Clinic within 2 weeks of most recent concussion

Exclusion Criteria:
Does not speak english
Periodontal disease
Ongoing seizure disorder, or other neurologic disorder
Drug or alcohol dependency
clinical diagnosis of severe TBI
Children's Health, Neurology, Sports Medicine
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Observations of Family Mealtime Routines

The purpose of this study is to gather information about what family mealtimes look like for families with children between the ages of 3 and 8. Families will be asked to video record their family mealtime, in addition to answer some questions and to complete some questionnaires, some about body image and dieting.

On one occasion, your family's mealtime will be recorded via Zoom. You and your family will be asked some questions and to complete some questionnaires online.

$20

No
 

Hannah Mudrick
Hannah Mudrick - at hxm99@psu.edu or 717-948-6404
Behavioral Sciences and Education (HARRISBURG)
 

All
All
This study is also accepting healthy volunteers
STUDY00015339
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
At least one adult who is the caregiver of at least one child between age 3 and 8 (e.g., at least one parent-child dyad)
Adults age 18 and older
Children, ages 3-8
Individuals fluent in English

Exclusion Criteria:
Non-family members, as defined individually by each family
Caregivers who are under the age of 18
Individuals who are not fluent in English
Families without at least one child age 3 to 8
Children's Health, Food & Nutrition
I'm interested
Share via email

PSCI 24-079 THE PHASE III ‘HIGH FIVE TRIAL’ FIVE FRACTION RADIATION FOR HIGH-RISK PROSTATE CANCER

This trial is comparing disease free survival using standard radiation versus higher doses of radiation to the prostate to prevent the cancer from spreading.

Participants will be chosen to enroll into one of two types of radiation to treat their prostate cancer. they must agree to keep all appointments over the 5 years period and agree to be contacted every year for follow up.

Yes
 

Zain Siddiqui
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Radiology (HERSHEY)
 

Male
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05946213
STUDY00025462
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of prostate cancer.
High-risk disease
Prostate gland volume less than 100 cc prior to initiation of ADT
o definitive clinical or radiologic evidence of metastatic disease
Age ≥ 18

Exclusion Criteria:
No prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields;
No prior radical prostatectomy;
Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both LHRH agonist and oral anti-androgen) is ≤ 185 days prior to registration;
Cancer
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Understanding Prenatal Hydration Behaviors

To examine women’s self-reported pregnancy hydration behaviors, especially during a global pandemic. This study will also examine other lifestyle behaviors (e.g., weight gain, exercise, eating behaviors, sleep, pain management). It is hypothesized that hydration behaviors will decrease due to lifestyle changes related to the pandemic. Secondary outcomes will also be influenced by hydration behaviors and pandemic lifestyle changes.

No
 

Danielle Downs
Abigail Pauley - at amp34@psu.edu
Kinesiology (UNIVERSITY PARK)
 

Female
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00016174
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pregnant
Women
18-45
English speaking

Exclusion Criteria:
Non-pregnant
Men
Younger than 18
Non-English speaking
Food & Nutrition, Mental & Behavioral Health, Women's Health
I'm interested
Share via email

Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease

This protocol has two independent parts. In Part 1, participants will be randomized to one of three Tulisokibart arms of treatment or placebo. Tretment will include induction, maintenance, and extension. When the maximum number of participants with prior exposure to advanced therapies has been reached, Part 2 will open for enrollment. In Part 2, the participants will be randomized to one of two dosing arms of Tulisokibart or a placebo.

The participants will be required to sign the inform consent and understand the requirements. They must have in person visits, comply with the procedures (blood test), colonoscopy, and to complete daily dairy about their symptoms. They must provide specimens such as blood, stool, and urine.

$100 per completed visit, $250 per endoscopy

Yes
 

Kofi Clarke
Zvjezdana (Stella) Sever Chroneos - at zchroneos1@pennstatehealth.psu.edu or 717-531-8259
Medicine: Gastroenterology and Hepatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06430801
STUDY00025295
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Read, understood, and provided written informed consent
Individual of any sex/gender from 18 years to 75 years of age inclusive,
Has had disease more than 3 months and has moderately active disease with one of the standard therapies
Average daily very soft or liquid SF ≥4 and/or average daily APS ≥2 at Baseline.
Demostrates loss of response, intolerance or inadequate response to standard therapy

Exclusion Criteria:
Has a diagnosis of UC, or indetermined colitis
Has CD without colonic involvement
Has known colonic stricture or colonic stenosis
Has current stoma
Is missing more than two colonic segments or has short bowel syndrome
Digestive Systems & Liver Disease
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI# 25-018 Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment Versus Standard of Care Treatment for Resectable State II/IV Cutaneous Squamous Cell Carcinoma

This study is comparing standard of care surgery and after surgery radiation against pre-surgery immunotherapy, followed by surgery, followed by radiation and immunotherapy to determine which combination prevents cancer reoccurrence.

Participants must come to all scheduled study visits, all medications they are taking including over the counter and tell the study doctor how you are feeling. 7 visits; 3 blood draws; QOLs to be completed 5 times for Group 1 and 7 times for Group 2

Yes
 

Danh Pham
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06568172
STUDY00026574
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pathologically (histologically or cytologically) proven diagnosis of invasive cutaneous squamous cell carcinoma (CSCC) or regional lymph node or in-transit metastasis of CSCC.
Previously untreated or recurrent CSCC
Age ≥ 18
ECOG Performance Status of 0-2
Not Pregnant and Not Nursing

Exclusion Criteria:
No history of myocardial infarction within the last 6 months
No active infection requiring systemic antibiotics, antiviral, or antifungal treatments
No history of allogeneic stem cell transplantation, or autologous stem cell transplantation.
No prior systemic therapy for the study cancer
Cancer
Experimental drug compared to an approved drug
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Cutaneous Sarcoidosis

The purpose of this research is to measure clinical safety and efficacy (effectiveness) of oral brepocitinib in adults with cutaneous sarcoidosis. Participation in this study is expected to last for up to 24 weeks (about 6 months). During treatment period, visits will be scheduled about every 4 weeks. Participants will be assigned to 1 of 3 treatments, there is a chance of receiving a placebo (non active ingredient treatment) however, you will not know nor will the study team know what treatment you have been assigned too. In addition, throughout the study at different time points you will answer questions, take the study treatment as directed by the study team, have your skin examined (biopsy), have labs drawn, have an ECG, and a chest x-ray.

Participants will attend a total of 7 in person visits throughout the study and visits will be scheduled about every 4 weeks during the Treatment Period. During the study you will be asked to answer questions to gather information on your health as well have you complete questionnaires. In addition, you will have the following assessments at different time points throughout the study: skin exam, ECG, Chest X-Ray, Skin photography, Skin punch biopsy, Pulmonary function testing, and blood tests.

Yes
 

Matthew Helm
Dermatology Clinical Trials at dermatologyclinicaltrials@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06978725
STUDY00026360
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be 18-75 years of age
Skin biopsy required along with presentation of cutaneous sacroidosis symptoms for 6 months or longer
Weight requirements apply for participation, study coordinator will discuss
Must be willing to understand and comply with the study requirements
Certain medications are allowed at a maximum stable dose, study coordinator will discuss further

Exclusion Criteria:
Medical History will be discussed with study coordinator.
Women who are breastfeeding, pregnant, or planning to become pregnant, or WOCBP who are unwilling to apply a highly effect birth control method for the time specified during study participation
Skin Conditions
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Making Second Language Learning More Inclusive in the Elementary Classroom: A Metalinguistic and Multimodal Approach

This study aims to find out whether learning German can help children with language difficulties improve their English skills. Children will learn German grammar using colors, shapes, and simple explanations to help them understand how language works.

Participants will complete 20 one-hour Zoom sessions over 10 weeks. During these sessions, they will learn German using a visual and interactive approach that highlights both similarities and differences between German and English. Some sessions will involve fun learning activities, while others will include assessments of language, cognitive, and metalinguistic skills.

$300

No
 

Natacha Mally
Natacha Mally - at nmally@psu.edu
Division of Graduate Studies (UNIVERSITY PARK)
 

All
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT00000000
STUDY00026229
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Children who likely have developmental language disorder (DLD; SLI)
Aged 7-11
Have English as their first language
Have significant difficulties understanding and/or expressing themselves in English

Exclusion Criteria:
Have a diagnosis of a neurodevelopmental disorder other than DLD (e.g., autism, ADHD, intellectual disability)
Are suspected of having another neurodevelopmental disorder, based on parent report or observed behavior
Have a hearing impairment
Children's Health, Education, Language & Linguistics
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov

A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Study to look at the safety and effectiveness of Obexelimab in patients with active Lupus who are currently receiving standard of care medications

There will be 13 in person visit over nine months, blood and urine will be obtained at 12 of these visits.

up to $650

Yes
 

Nancy Olsen
Jamie Carter - at jcarter3@pennstatehealth.psu.edu
Medicine: Rheumatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06559163
STUDY00025867
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Systemic Lupus

Exclusion Criteria:
Active Lupus Nephritis
over 70 years old
Arthritis & Rheumatic Diseases
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Voice Assistant to Provide Cognitive Stimulation Therapy at Scale

This project focuses on establishing a preliminary evidence base regarding the feasibility and acceptability of using smart speakers to deliver individual cognitive stimulation therapy (iCST) to persons living with dementia (PLwDs)

Fifteen dyads of persons living with dementia and their care partners will be recruited. Participants will engage with an Alexa-based Virtual Assistant (VA), and data will be collected via surveys and Zoom interviews.

$45 per hour

No
 

Saeed Abdullah
Ita Saragih - at ixs5315@psu.edu or 582-203-8955
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00024129
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Family care partner and their family member with mild dementia
Ability to speak and understand English
See and hear well enough to participate
No major physical illness or disability affecting their participation
Personal in-home Wi-Fi access and personal device capable of participating in Zoom calls

Exclusion Criteria:
Persons living with dementia or their care partners who are unable to provide inform consent
Neurology, Mental & Behavioral Health
I'm interested
Share via email

PSCI# 25-028 LoTAM: A RANDOMIZED, PHASE III CLINICAL TRIAL OF LOW-DOSE TAMOXIFEN FOR SELECTED PATIENTS WITH MOLECULAR LOW-RISK EARLY-STAGE BREAST CANCER

This study is comparing standard of care endocrine therapy for 5 years versus low dose tamoxifen for 5 years in patients with resected invasive breast cancer.

Participants must come to all scheduled study visits, all medications they are taking including over the counter and tell the study doctor how you are feeling.

Yes
 

Cristina Truica
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06671912
STUDY00026751
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Unilateral invasive adenocarcinoma of the breast that is histologically confirmed
No tumors that are considered pT4
No definitive clinical or radiologic evidence of metastatic disease
Age ≥ 18 years and female ___
ECOG Performance Status ≤ 2

Exclusion Criteria:
Abnormal or dysfunctional uterine bleeding within 1 year prior to study enrollment
Any patient with known atypia or endometrial pathology that the opinion of the treating investigator would place the patient at undue risk of endometrial cancer with tamoxifen
Any patient with a known hypercoagulable state that in the opinion of the treating investigator would put the patient at undue risk of venous thromboembolism with tamoxifen.
No synchronous or previous contralateral invasive or non-invasive breast
No previous history of ipsilateral invasive breast cancer or ipsilateral DCIS, regardless of the disease-free interval.
Cancer
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,